Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ETON
$18.28
$
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Next Earnings
2026-02-25
Beta
1.216
Average Volume
Market Cap
Last Dividend
CIK
0001710340
ISIN
US29772L1089
CUSIP
29772L108
CEO
Sean E. Brynjelsen
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
31
IPO Date
2018-11-13
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th | DEER PARK, Ill., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host one-on-one meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026 in Miami, Florida. | GlobeNewsWire | 2026-02-20 06:50:00 |
| Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate | DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the licensing of U.S. marketing rights to an ultra-rare disease product candidate. Once approved, the product is expected to be the first and only generic alternative to a product used to treat an ultra-rare condition that impacts fewer than 100 patients in the United States. | GlobeNewsWire | 2026-02-02 06:50:00 |
| Eton Pharmaceuticals: An Undervalued Small Cap With High Growth | Eton offers a diversified, acquisition-driven portfolio in ultra-rare pediatric endocrinology and metabolic diseases, targeting significant peak sales potential. My DCF-based Fair Value is $28.1, representing 85% upside; optimistic scenarios suggest up to $40 per share, while downside risk is mitigated by product diversification. Revenue growth, free cash flow positivity, and declining SG&A margins support a Buy-to-Strong Buy stance at $15.17, despite high uncertainty from US drug pricing. | Seeking Alpha | 2026-01-23 10:20:07 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-05 | 2026-02-05 | View Filing |
| 8-K | 2026-02-02 | 2026-02-02 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| 8-K | 2025-12-04 | 2025-12-04 | View Filing |
| S-8 | 2025-11-19 | 2025-11-19 | View Filing |
| 8-K/A | 2025-11-18 | 2025-11-18 | View Filing |
| 10-Q | 2025-11-06 | 2025-11-06 | View Filing |
| 8-K | 2025-11-06 | 2025-11-06 | View Filing |
| SC 13G | 2025-10-30 | 2025-10-30 | View Filing |
| 4 | 2025-08-20 | 2025-08-20 | View Filing |
| 10-Q | 2025-08-07 | 2025-08-07 | View Filing |
| 8-K | 2025-08-07 | 2025-08-07 | View Filing |
| SC 13G | 2025-07-17 | 2025-07-17 | View Filing |
| 8-K | 2025-07-08 | 2025-07-08 | View Filing |
| 8-K | 2025-06-27 | 2025-06-27 | View Filing |
| 8-K | 2025-06-20 | 2025-06-20 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 8-K | 2025-06-10 | 2025-06-10 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| 8-K | 2025-05-28 | 2025-05-28 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K/A | 2025-05-02 | 2025-05-02 | View Filing |
| 8-K | 2025-04-28 | 2025-04-28 | View Filing |
| DEF 14A | 2025-04-25 | 2025-04-25 | View Filing |
| 8-K | 2025-04-01 | 2025-04-01 | View Filing |
| 8-K | 2025-03-18 | 2025-03-18 | View Filing |
| 8-K | 2025-03-18 | 2025-03-18 | View Filing |
| 10-K | 2025-03-18 | 2025-03-18 | View Filing |
| 8-K | 2025-03-14 | 2025-03-14 | View Filing |
| 8-K/A | 2025-03-07 | 2025-03-07 | View Filing |
| 8-K | 2025-03-03 | 2025-03-03 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| 8-K | 2025-02-07 | 2025-02-07 | View Filing |
| 8-K | 2025-02-06 | 2025-02-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 8-K | 2025-01-03 | 2025-01-03 | View Filing |
| 8-K | 2024-12-20 | 2024-12-20 | View Filing |
| 8-K | 2024-12-17 | 2024-12-17 | View Filing |
| 8-K | 2024-12-12 | 2024-12-12 | View Filing |
| 424B5 | 2024-12-12 | 2024-12-12 | View Filing |
| 3 | 2024-12-09 | 2024-12-09 | View Filing |
| SC 13G | 2024-12-09 | 2024-12-09 | View Filing |
| 8-K | 2024-12-03 | 2024-12-03 | View Filing |
| 8-K | 2024-11-25 | 2024-11-25 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-07 | 2024-11-07 | View Filing |
| 4 | 2024-10-25 | 2024-10-25 | View Filing |
| 4 | 2024-10-08 | 2024-10-08 | View Filing |
| 4 | 2024-10-04 | 2024-10-04 | View Filing |
| 8-K | 2024-10-03 | 2024-10-03 | View Filing |
| 4 | 2024-09-12 | 2024-09-12 | View Filing |
| SC 13G/A | 2024-09-12 | 2024-09-12 | View Filing |
| 3 | 2024-09-12 | 2024-09-12 | View Filing |
| 10-Q | 2024-08-08 | 2024-08-08 | View Filing |
| 8-K | 2024-08-08 | 2024-08-08 | View Filing |
| 8-K/A | 2024-08-02 | 2024-08-02 | View Filing |
| 8-K | 2024-07-15 | 2024-07-15 | View Filing |
| 8-K | 2024-06-21 | 2024-06-21 | View Filing |
| 8-K | 2024-06-11 | 2024-06-11 | View Filing |
| 10-Q | 2024-05-09 | 2024-05-09 | View Filing |
| 8-K | 2024-05-09 | 2024-05-09 | View Filing |
| 8-K | 2024-04-30 | 2024-04-30 | View Filing |
| SC 13D/A | 2024-04-30 | 2024-04-30 | View Filing |
| DEF 14A | 2024-04-26 | 2024-04-26 | View Filing |
| 8-K | 2024-04-18 | 2024-04-18 | View Filing |
| S-8 | 2024-03-26 | 2024-03-26 | View Filing |
| 10-K/A | 2024-03-22 | 2024-03-22 | View Filing |
| 8-K | 2024-03-22 | 2024-03-22 | View Filing |
| 10-K | 2024-03-14 | 2024-03-14 | View Filing |
| 8-K | 2024-03-14 | 2024-03-14 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Swarm Intelligence Strategy | 12.19% | 1 | 635 | 0.01 | 0.04 | 18.3 |
| Williams PercentR Strategy | 11.51% | 1 | 242 | 0.02 | 0.04 | 17.62 |
| Bollinger Bands Strategy | 7.65% | 1 | 72 | 0.01 | 0.03 | 13.75 |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxx% | x | xxx | x | xxxx | xxxxx |
| xxx | xxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | x | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | x | xxxxx | xxxx | x |
| xxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |